[{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Ascentage Pharma"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allorion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allorion Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Allorion Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"St. Jude Children \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Cancer Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Zhejiang Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Cancer Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Cancer Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"National Cancer Center, Japan","sponsor":"Pfizer Inc | Korean Cancer Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Center, Japan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Center, Japan \/ Pfizer Inc | Korean Cancer Study Group","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Center, Japan \/ Pfizer Inc | Korean Cancer Study Group"},{"orgOrder":0,"company":"Kyoto Breast Cancer Research Network","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Kyoto Breast Cancer Research Network","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyoto Breast Cancer Research Network \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Kyoto Breast Cancer Research Network \/ Pfizer Inc"},{"orgOrder":0,"company":"Samsung Medical Center","sponsor":"Korean Cancer Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Samsung Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Medical Center \/ Korean Cancer Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Samsung Medical Center \/ Korean Cancer Study Group"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSN Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MSN Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"iOMEDICO","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"iOMEDICO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"iOMEDICO \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"iOMEDICO \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Ulm","sponsor":"Pfizer Inc | National Center for Tumor Diseases, Heidelberg","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Ulm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulm \/ Pfizer Inc | National Center for Tumor Diseases, Heidelberg","highestDevelopmentStatusID":"7","companyTruncated":"University of Ulm \/ Pfizer Inc | National Center for Tumor Diseases, Heidelberg"},{"orgOrder":0,"company":"GBG Forschungs GmbH","sponsor":"Pfizer Inc | AMS Advanced Medical Services","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase IV","graph3":"GBG Forschungs GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GBG Forschungs GmbH \/ Pfizer Inc | AMS Advanced Medical Services","highestDevelopmentStatusID":"11","companyTruncated":"GBG Forschungs GmbH \/ Pfizer Inc | AMS Advanced Medical Services"},{"orgOrder":0,"company":"GBG Forschungs GmbH","sponsor":"Pfizer Inc | AGO Study Group | NSABP Foundation | Breast International Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase IV","graph3":"GBG Forschungs GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GBG Forschungs GmbH \/ Pfizer Inc | AGO Study Group | NSABP Foundation | Breast International Group","highestDevelopmentStatusID":"11","companyTruncated":"GBG Forschungs GmbH \/ Pfizer Inc | AGO Study Group | NSABP Foundation | Breast International Group"},{"orgOrder":0,"company":"NSGO-CTU","sponsor":"European Network for Gynaecological Oncological Trial Groups | Gynecologic Cancer Intergroup | North Eastern German Society of Gynaecological Oncology | Multicenter Italian Trials in Ovarian Cancer | Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Ovario","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"NSGO-CTU","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NSGO-CTU \/ European Network for Gynaecological Oncological Trial Groups | Gynecologic Cancer Intergroup | North Eastern German Society of Gynaecological Oncology | Multicenter Italian Trials in Ovarian Cancer | Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Ovario","highestDevelopmentStatusID":"8","companyTruncated":"NSGO-CTU \/ European Network for Gynaecological Oncological Trial Groups | Gynecologic Cancer Intergroup | North Eastern German Society of Gynaecological Oncology | Multicenter Italian Trials in Ovarian Cancer | Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Ovario"},{"orgOrder":0,"company":"UNICANCER","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNICANCER \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"UNICANCER \/ Pfizer Inc"},{"orgOrder":0,"company":"UNICANCER","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNICANCER \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"UNICANCER \/ Pfizer Inc"},{"orgOrder":0,"company":"Spanish Breast Cancer Research Group","sponsor":"Pfizer Inc | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Spanish Breast Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Breast Cancer Research Group \/ Pfizer Inc | AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Spanish Breast Cancer Research Group \/ Pfizer Inc | AstraZeneca"},{"orgOrder":0,"company":"SOLTI Breast Cancer Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"SOLTI Breast Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOLTI Breast Cancer Research Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SOLTI Breast Cancer Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Spanish Breast Cancer Research Group","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Spanish Breast Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Breast Cancer Research Group \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Spanish Breast Cancer Research Group \/ AstraZeneca"},{"orgOrder":0,"company":"Grupo Espa\u00f1ol de Investigaci\u00f3n en Neurooncolog\u00eda","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Grupo Espa\u00f1ol de Investigaci\u00f3n en Neurooncolog\u00eda","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espa\u00f1ol de Investigaci\u00f3n en Neurooncolog\u00eda \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Grupo Espa\u00f1ol de Investigaci\u00f3n en Neurooncolog\u00eda \/ Pfizer Inc"},{"orgOrder":0,"company":"SOLTI Breast Cancer Research Group","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"SOLTI Breast Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOLTI Breast Cancer Research Group \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"SOLTI Breast Cancer Research Group \/ Pfizer Inc"},{"orgOrder":0,"company":"Region \u00d6rebro County","sponsor":"University of Patras | University of Florence | Azienda USL Toscana Centro | Helsinki University Central Hospital | Institute for Medical Technology Assessment - the Netherlands | Security Labs Consulting Limited | Circular Economy Foundation | Universida","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Region \u00d6rebro County","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Region \u00d6rebro County \/ University of Patras | University of Florence | Azienda USL Toscana Centro | Helsinki University Central Hospital | Institute for Medical Technology Assessment - the Netherlands | Security Labs Consulting Limited | Circular Economy Foundation | Universida","highestDevelopmentStatusID":"10","companyTruncated":"Region \u00d6rebro County \/ University of Patras | University of Florence | Azienda USL Toscana Centro | Helsinki University Central Hospital | Institute for Medical Technology Assessment - the Netherlands | Security Labs Consulting Limited | Circular Economy Foundation | Universida"},{"orgOrder":0,"company":"ETOP IBCSG Partners Foundation","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"ETOP IBCSG Partners Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ETOP IBCSG Partners Foundation \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"ETOP IBCSG Partners Foundation \/ Pfizer Inc"},{"orgOrder":0,"company":"ETOP IBCSG Partners Foundation","sponsor":"Breast International Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"ETOP IBCSG Partners Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ETOP IBCSG Partners Foundation \/ Breast International Group","highestDevelopmentStatusID":"10","companyTruncated":"ETOP IBCSG Partners Foundation \/ Breast International Group"},{"orgOrder":0,"company":"ETOP IBCSG Partners Foundation","sponsor":"Pfizer Inc | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"ETOP IBCSG Partners Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ETOP IBCSG Partners Foundation \/ Pfizer Inc | F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"ETOP IBCSG Partners Foundation \/ Pfizer Inc | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Royal Marsden NHS Foundation Trust","sponsor":"Pfizer Inc | AstraZeneca | Institute of Cancer Research, United Kingdom | UNICANCER | Gustave Roussy | Invitae","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Royal Marsden NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Royal Marsden NHS Foundation Trust \/ Pfizer Inc | AstraZeneca | Institute of Cancer Research, United Kingdom | UNICANCER | Gustave Roussy | Invitae","highestDevelopmentStatusID":"8","companyTruncated":"Royal Marsden NHS Foundation Trust \/ Pfizer Inc | AstraZeneca | Institute of Cancer Research, United Kingdom | UNICANCER | Gustave Roussy | Invitae"},{"orgOrder":0,"company":"Royal Marsden NHS Foundation Trust","sponsor":"Pfizer Inc | Breast Cancer Now","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Royal Marsden NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal Marsden NHS Foundation Trust \/ Pfizer Inc | Breast Cancer Now","highestDevelopmentStatusID":"6","companyTruncated":"Royal Marsden NHS Foundation Trust \/ Pfizer Inc | Breast Cancer Now"},{"orgOrder":0,"company":"biotx.ai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"biotx.ai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"biotx.ai \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"biotx.ai \/ Undisclosed"},{"orgOrder":0,"company":"Royal Marsden NHS Foundation Trust","sponsor":"Institute of Cancer Research, United Kingdom | F. Hoffmann-La Roche | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Royal Marsden NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal Marsden NHS Foundation Trust \/ Institute of Cancer Research, United Kingdom | F. Hoffmann-La Roche | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Royal Marsden NHS Foundation Trust \/ Institute of Cancer Research, United Kingdom | F. Hoffmann-La Roche | Pfizer Inc"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEDSIR \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MEDSIR \/ Undisclosed"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEDSIR \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MEDSIR \/ Undisclosed"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEDSIR \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"MEDSIR \/ Pfizer Inc"},{"orgOrder":0,"company":"Palleos Healthcare","sponsor":"WSG Women\u2019s Healthcare Study Group | Cankado | Pfizer Inc | AGO-TraFo | AGO-B | Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e.V.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase IV","graph3":"Palleos Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palleos Healthcare \/ WSG Women\u2019s Healthcare Study Group | Cankado | Pfizer Inc | AGO-TraFo | AGO-B | Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e.V.","highestDevelopmentStatusID":"11","companyTruncated":"Palleos Healthcare \/ WSG Women\u2019s Healthcare Study Group | Cankado | Pfizer Inc | AGO-TraFo | AGO-B | Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e.V."},{"orgOrder":0,"company":"International Cancer Research Group, United Arab Emirates","sponsor":"King Saud Medical City | Max-Planck-Institut f\u00fcr Quantenoptik (MPQ), and Faculty of Physics at Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen (LMU), Garching, Germany | King Abdallah University for Science and Technology (KAUST), Thuwal, Saudi Arabia.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.A.E","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"International Cancer Research Group, United Arab Emirates","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Cancer Research Group, United Arab Emirates \/ King Saud Medical City | Max-Planck-Institut f\u00fcr Quantenoptik (MPQ), and Faculty of Physics at Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen (LMU), Garching, Germany | King Abdallah University for Science and Technology (KAUST), Thuwal, Saudi Arabia.","highestDevelopmentStatusID":"8","companyTruncated":"International Cancer Research Group, United Arab Emirates \/ King Saud Medical City | Max-Planck-Institut f\u00fcr Quantenoptik (MPQ), and Faculty of Physics at Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen (LMU), Garching, Germany | King Abdallah University for Science and Technology (KAUST), Thuwal, Saudi Arabia."},{"orgOrder":0,"company":"University of Arizona","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Arizona \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Arizona \/ Pfizer Inc"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of California, San Francisco \/ Pfizer Inc"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Children's Oncology Group \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Georgetown University \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Georgetown University \/ Pfizer Inc"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Georgetown University \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Georgetown University \/ Pfizer Inc"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Georgetown University \/ Pfizer Inc"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Pfizer Inc | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Pfizer Inc | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Northwestern University \/ Pfizer Inc | National Cancer Institute"},{"orgOrder":0,"company":"Canadian Cancer Trials Group","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Canadian Cancer Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Cancer Trials Group \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Canadian Cancer Trials Group \/ Pfizer Inc"},{"orgOrder":0,"company":"Canadian Cancer Trials Group","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Canadian Cancer Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Cancer Trials Group \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Canadian Cancer Trials Group \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Kansas Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Kansas Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kansas Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Kansas Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Pfizer Inc"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Leukemia and Lymphoma Society | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Leukemia and Lymphoma Society | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Leukemia and Lymphoma Society | Pfizer Inc"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Takeda Pharmaceutical | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Takeda Pharmaceutical | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Weill Medical College of Cornell University \/ Takeda Pharmaceutical | Pfizer Inc"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Celgene Corporation | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Celgene Corporation | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Weill Medical College of Cornell University \/ Celgene Corporation | Pfizer Inc"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Alliance Foundation Trials","sponsor":"Austrian Breast & Colorectal Cancer Study Group | NSABP Foundation | PrECOG | Breast International Group | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Alliance Foundation Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alliance Foundation Trials \/ Austrian Breast & Colorectal Cancer Study Group | NSABP Foundation | PrECOG | Breast International Group | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Alliance Foundation Trials \/ Austrian Breast & Colorectal Cancer Study Group | NSABP Foundation | PrECOG | Breast International Group | Pfizer Inc"},{"orgOrder":0,"company":"Alliance Foundation Trials","sponsor":"Pfizer Inc | GBG Forschungs GmbH | Fondazione Michelangelo | PrECOG | Breast Cancer Trials | Syneos Health | SOLTI Breast Cancer Research Group | UNICANCER","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Alliance Foundation Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alliance Foundation Trials \/ Pfizer Inc | GBG Forschungs GmbH | Fondazione Michelangelo | PrECOG | Breast Cancer Trials | Syneos Health | SOLTI Breast Cancer Research Group | UNICANCER","highestDevelopmentStatusID":"10","companyTruncated":"Alliance Foundation Trials \/ Pfizer Inc | GBG Forschungs GmbH | Fondazione Michelangelo | PrECOG | Breast Cancer Trials | Syneos Health | SOLTI Breast Cancer Research Group | UNICANCER"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Pfizer Inc"},{"orgOrder":0,"company":"Alliance Foundation Trials","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Alliance Foundation Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alliance Foundation Trials \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alliance Foundation Trials \/ Pfizer Inc"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Pfizer Inc"},{"orgOrder":0,"company":"American Society of Clinical Oncology","sponsor":"AstraZeneca | Bayer AG | Bristol Myers Squibb | Eli Lilly | Genentech | Merck & Co | Pfizer Inc | Boehringer Ingelheim GmbH | Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"American Society of Clinical Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Society of Clinical Oncology \/ AstraZeneca | Bayer AG | Bristol Myers Squibb | Eli Lilly | Genentech | Merck & Co | Pfizer Inc | Boehringer Ingelheim GmbH | Taiho Oncology","highestDevelopmentStatusID":"8","companyTruncated":"American Society of Clinical Oncology \/ AstraZeneca | Bayer AG | Bristol Myers Squibb | Eli Lilly | Genentech | Merck & Co | Pfizer Inc | Boehringer Ingelheim GmbH | Taiho Oncology"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Nephrology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Pfizer Inc | University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ Pfizer Inc | University of Pennsylvania","highestDevelopmentStatusID":"6","companyTruncated":"UT Southwestern Medical Center \/ Pfizer Inc | University of Pennsylvania"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc | Joseph Sanchez Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc | Joseph Sanchez Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc | Joseph Sanchez Foundation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc | Rising Tide Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc | Rising Tide Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc | Rising Tide Foundation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Pfizer Inc | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Pfizer Inc | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Pfizer Inc | Merck & Co"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Children's Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Children's Oncology Group","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Children's Oncology Group"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Fundacion Oncosur","sponsor":"Pfizer Inc | Apices Soluciones | Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHILE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fundacion Oncosur","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundacion Oncosur \/ Pfizer Inc | Apices Soluciones | Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Fundacion Oncosur \/ Pfizer Inc | Apices Soluciones | Pierre Fabre"},{"orgOrder":0,"company":"Megalabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Megalabs \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Megalabs \/ Undisclosed"},{"orgOrder":0,"company":"Latin American Cooperative Oncology Group","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Latin American Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Latin American Cooperative Oncology Group \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Latin American Cooperative Oncology Group \/ Pfizer Inc"},{"orgOrder":0,"company":"European Organisation for Research and Treatment of Cancer","sponsor":"Pfizer Inc | Swedish Association of Breast Oncologists | ETOP IBCSG Partners Foundation | German Adjuvant Breast Cancer Group | SOLTI Breast Cancer Research Group | UNICANCER | Gruppo Oncologico Italiano di Ricerca Clinica | Breast International Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"European Organisation for Research and Treatment of Cancer","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"European Organisation for Research and Treatment of Cancer \/ Pfizer Inc | Swedish Association of Breast Oncologists | ETOP IBCSG Partners Foundation | German Adjuvant Breast Cancer Group | SOLTI Breast Cancer Research Group | UNICANCER | Gruppo Oncologico Italiano di Ricerca Clinica | Breast International Group","highestDevelopmentStatusID":"8","companyTruncated":"European Organisation for Research and Treatment of Cancer \/ Pfizer Inc | Swedish Association of Breast Oncologists | ETOP IBCSG Partners Foundation | German Adjuvant Breast Cancer Group | SOLTI Breast Cancer Research Group | UNICANCER | Gruppo Oncologico Italiano di Ricerca Clinica | Breast International Group"},{"orgOrder":0,"company":"Criterium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Criterium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Criterium \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Criterium \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Palbociclib","moa":"||Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase kidney isoform, mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Paradigm BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Palazestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Olema Oncology","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Olema Oncology \/ Paradigm BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"Olema Oncology \/ Paradigm BioCapital"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Olema Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Olema Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olema Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Olema Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olema Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Olema Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Olema Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Palazestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Olema Oncology","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Olema Oncology"},{"orgOrder":0,"company":"Arvinas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2020","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2021","type":"Collaboration","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":2.0499999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.0499999999999998,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Relay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Relay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Nextech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foundation Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Onapristone","moa":"||Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Menarini","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alphamab Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"KN026","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Alphamab Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Alphamab Oncology"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Fulvestrant","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zymeworks \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Pfizer Inc"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zymeworks \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Undisclosed"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Celcuity","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"IND Enabling","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celcuity \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Celcuity \/ Pfizer Inc"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Gedatolisib","moa":"||Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tvardi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2025","type":"Collaboration","leadProduct":"Vepdegestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":2.0499999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.0499999999999998,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Oana Danciu, MD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Oana Danciu, MD","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Oana Danciu, MD"}]
Find Clinical Drug Pipeline Developments & Deals for Palbociclib
Details :
PRIMCYV® is a targeted therapy containing the active constituent palbociclib, a first-in-class CDK 4/6 inhibitor indicated in combination with an aromatase inhibitor for the first-line treatment of adult patients with HR+, HER2- metastatic breast cancer...
Details :
The pivotal study (AMEERA-3) of amcenestrant versus physician’s choice in locally advanced or metastatic estrogen receptor-positive (ER+) breast cancer is fully recruited; readout expected in H2 2021.
Details :
Dr. Reddy’s Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe is available in a carton containing two 5 mL single-dose prefilled syringes.
Details :
Company going to present clinical data on its oncology portfolio including data on its Phase 1/2 study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/HER2- metastatic breast cancer.
Details :
Thew proceeds will be used to advance Avenzo’s portfolio of potential best-in-class oncology drug candidates, including AVZO-021, the company’s lead drug candidate.
Details :
The collaboration aims for the co-development of ARV-471 (vepdegestrant), an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader.
Details :
Itovebi (inavolisib) is a kinase inhibitor indicated with palbociclib for treating endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer.
Details :
AZD9833 (camizestrant) is an investigational, potent, next-generation oral SERD and ER antagonist that is currently being investigated for the treatment of HR-positive breast cancer.
Details :
GDC-0077 (inavolisib) is a PI3K alpha Inhibitor in combination with palbociclib and fulvestran, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer.
Details :
RLY-2608 is a PI3K alpha inhibitor, small molecule, which is being evaluated for the treatment of patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
